Halol Plant Approvals Still On Hold As Sun Responds To Lengthy FDA Inspection Report
Executive Summary
After years of pandemic-related delays, US FDA reinspects key Sun plant in Halol, India, hit with “official action indicated” inspection findings that tabled approvals just before COVID-19 impeded travel. However, new findings are generating further discussions.
You may also be interested in...
The Quality Lowdown: As Washington Churns On Drug Shortages, Supply Chain Challenges Grow
While FDA commissioner meets with firms on shortages, senators challenge alternative source of platinum chemotherapies, FDA hinges imports from Sun plant on successful media fill runs, Safe Chain warned on Biktarvy suppliers, and the FDA asks Ipca more questions while setting “Mr. Ye” straight.
Internal FDA Guidance Further Constrains GDUFA III Get-Out-Of-OAI Card
Generic drug firms won a narrow commitment from the US FDA to approve ANDAs without revisiting sites previously deemed deficient. But the agency's just-issued MAPP document implementing the commitment, which stems from pandemic-era travel frustrations, is narrower still. Recent reinspection results might explain why.
Internal FDA Guidance Further Constrains GDUFA III Get-Out-Of-OAI Card
Generic drug firms won a narrow commitment from the US FDA to approve ANDAs without revisiting sites previously deemed deficient. But the agency's just-issued MAPP document implementing the commitment, which stems from pandemic-era travel frustrations, is narrower still. Recent reinspection results might explain why.